back to events
Natco Pharma Clarification on Semaglutide Deal with Eris Lifesciences
regulatory_filingPositive
confidence: 95%
Description
Natco Pharma Limited submitted a response to the NSE clarifying news regarding a commercial agreement with Eris Lifesciences for the weight-loss drug semaglutide.